The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved October 1997

Specific Treatments:

benign prostatic hypertrophy (BPH)

Find Related Trials for The Following Conditions

General Information

FLOMAX has been approved for the treatment of benign prostatic hypertrophy (BPH). Boehringer Ingelheim, which licensed the product from originator Yamanouchi, will market the product in the U.S.